RUNX1 Antibodies

Santa Cruz Biotechnology delivers a wide array of RUNX1 monoclonal antibodies for research focused on understanding RUNX1 protein functions. RUNX1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). RUNX1, also known as AML1, is a transcription factor that plays a pivotal role in hematopoiesis and the development of blood cells. RUNX1 regulates genes involved in cell differentiation and proliferation, making it a key player in both normal and malignant hematopoietic processes. Mutations and alterations in RUNX1 expression are frequently observed in various blood disorders and leukemias. Understanding RUNX1's molecular mechanisms and interactions provides valuable insights into blood cell development and potential therapeutic targets. Studying RUNX1's role in normal development helps researchers better understand its involvement in disease progression. Research involving RUNX1 continues to reveal new aspects of blood cell formation and regulation. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance their understanding of RUNX1's role in health and disease, contributing to potential therapeutic breakthroughs in hematological conditions.